Table 2.
Flow Cytometry Analysis of Surface Markers of Xenograft Cells, PLC Cell Line, and Human Primary Hepatocytes
| Tumor cells by subpopulations | Control | CD34 | CD31 | CD54 | CD90 | EpCAM | CD44 | CD133 | CD13 | OV6 |
|---|---|---|---|---|---|---|---|---|---|---|
| CD34+CD133− | 0.5±0.1 | 3.0±0.1 | 3.0±0.7 | 99±0.1 | 4.4±1.6 | 51±19 | 12±0.8 | 66±14 | 89±2.3 | 6.9±0.8 |
| CD34+CD133+ | 0.4±0.1 | 2.7±0.1 | 1.1±0.3 | 99±0.2 | 1.6±0.5 | 74±15 | 12±2.4 | 77±6.4 | 94±0.4 | 4.9±0.3 |
| CD34−CD133+ | 0.7±0.3 | 1.3±0.7 | 4.8±0.1 | 92±4.9 | 7.5±3.4 | 85±6.5 | 7.4±4.6 | 76±14 | 99±0.8 | 5.2±0.3 |
| CD34+CD44− | 0.5±0.2 | 5.2±1.1 | 5.0±0.2 | 99±0.6 | 5.4±0.3 | 83±4.5 | 9.0±0.7 | 62±2.4 | 85±4.3 | 7.0±0.7 |
| CD34+CD44+ | 0.5±0.2 | 6.6±1.9 | 14±1.4 | 99±0.1 | 3.3±1.2 | 71±4.8 | 31±7.1 | 29±8.6 | 93±0.9 | 15±0.6 |
| CD34−CD44+ | 0.4±0.2 | 1.1±0.3 | 62±3.1 | 99±0.8 | 1.7±0.6 | 30±6.2 | 38±6.8 | 8.7±2.5 | 91±4.4 | 17±1.1 |
| CD34+CD90− | 0.6±0.1 | 4.3±1.7 | 10±4.6 | 98±0.5 | 4.6±0.6 | 33±10 | 30±16 | 71±13 | 68±23 | 4.1±0.3 |
| CD34+CD90+ | 0.5±0.2 | 4.7±0.3 | 3.7±1.5 | 99±0.8 | 11±6.6 | 92±5.8 | 7.9±1.9 | 49±26 | 89±1.7 | 8.7±1.3 |
| CD34−CD90+ | 0.7±0.2 | 1.9±0.2 | 3.6±1.1 | 99±0.9 | 5.4±1.3 | 69±8.9 | 14±2.2 | 76±6.5 | 97±1.1 | 6.7±1.0 |
| CD34+CD31− | 0.5±0.1 | 5.3±2.9 | 3.0±0.5 | 99±0.1 | 4.2±0.8 | 81±12 | 13±5.4 | 84±16 | 95±1.7 | 5.3±1.1 |
| CD34+CD31+ | 0.5±0.1 | 3.2±0.8 | 23±7.8 | 99±0.2 | 4.3±0.9 | 66±7.2 | 30±6.3 | 77±4.5 | 92±1.8 | 18±0.6 |
| CD34−CD31+ | 0.6±0.1 | 1.9±0.1 | 89±11 | 95±3.5 | 3.6±1.4 | 27±9.8 | 65±4.8 | 21±8.8 | 99±0.2 | 18±0.8 |
| CD34+EpCAM− | 0.6±0.2 | 3.6±1.1 | 8.2±3.6 | 99±0.1 | 3.5±0.7 | 40±9.0 | 11±0.3 | 64±11 | 90±4.4 | 8.1±1.8 |
| CD34+EpCAM+ | 0.5±0.1 | 4.2±2.0 | 6.2±3.6 | 99±0.2 | 4.5±1.1 | 97±1.8 | 19±1.7 | 78±1.6 | 94±2.6 | 8.9±2.2 |
| CD34−EpCAM+ | 0.6±0.1 | 1.8±1.5 | 3.6±1.2 | 99±0.9 | 2.8±0.3 | 86±9.0 | 13±5.3 | 74±5.1 | 90±0.8 | 11±0.6 |
| CD34+OV6− | 0.6±0.2 | 3.6±0.5 | 8.2±1.7 | 98±0.9 | 3.6±0.5 | 78±9.5 | 15±3.2 | 59±5.8 | 96±1.1 | 6.2±0.3 |
| CD34+OV6+ | 0.6±0.1 | 2.6±0.6 | 15±7.4 | 98±1.0 | 6.2±1.3 | 88±8.6 | 28±3.1 | 42±7.6 | 95±2.1 | 18±0.6 |
| CD34−OV6+ | 0.7±0.1 | 1.1±0.5 | 71±3.1 | 87±2.0 | 4.5±0.7 | 7.5±1.6 | 30±2.5 | 7.2±1.8 | 97±1.6 | 15±1.8 |
| CD34+ cells | 0.6±0.1 | 5.4±0.7 | 12±4.5 | 98±0.6 | 5.0±1.2 | 73±11 | 22±5.7 | 61±9.3 | 97±0.7 | 8.4±1.7 |
| PLC | 0.5±0.1 | 6.4±0.4 | 15±2.4 | 99±0.1 | 3.5±0.3 | 37±2.9 | 13±1.5 | 69±1.7 | 95±0.7 | 8.9±0.9 |
| CD34− PLC | 0.5±0.3 | 1.7±0.4 | 8.5±2.5 | 97±2.1 | 2.1±0.4 | 59±14 | 18±3.2 | 48±10 | 85±5.4 | 5.5±1.2 |
| PLC cell line | 0.4±0.1 | 6.8±0.9 | 4.8±2.0 | 99±0.3 | 1.1±0.1 | 14±3.2 | 3.3±1.2 | 76±3.0 | 97±0.4 | 12±3.1 |
| HPH | 0.4±0.1 | 1.1±0.3 | 1.6±0.5 | 64±2.7 | 0.5±0.1 | 1.4±0.3 | 2.6±0.3 | 0.6±0.1 | 78±4.3 | 16±5.4 |
The cells from xenografts produced by 21 cell populations, parental PLC line and human primary hepatocytes were stained with antibodies against nine surface markers, and the percentage of these markers were measured by flow cytometry. Data represent mean±SEM (4≤n≤11).